GLP-1 Agonists and Alzheimer’s Disease: A Comprehensive Review of the Evidence

There is emerging research on GLP-1 agonists, a class of drugs primarily used for type 2 diabetes and weight loss (e.g., Ozempic, Wegovy), that are being investigated for their potential to lower the risk and slow the progression of Alzheimer’s disease. “Large-scale studies of patient data have shown that individuals with type 2 diabetes taking GLP-1 agonists have a significantly lower incidence of Alzheimer’s disease compared to those on other diabetes medications. GLP-1 agonists are not currently approved by the FDA for the prevention or treatment of Alzheimer’s disease. Their use for this purpose is still experimental.”

Mahalo to Elliot Tindell and students for sharing this resource!